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Table 1
Systems Symptoms
G-I Nausea vomiting abdominal pain cramping
Respiratory Cough dys/tachypnoea hypoxia SOB TRALI
Cardiac Hypo/hypertension brady/tachycardia arrhythmia chest
heaviness/pain MI cardiac arrest
Neuro Amnesia seizure stroke numbness uc
Other Fever chills ﬂushing headache hypothermia anxiety
vertigo allergy visual neuropathy back pain
Cause of SCIAR is either the graft (DMSO, cell content, volume, clumping) or
the patient (age, gender, disease).
Abstracts / Biol Blood Marrow Transplant 21 (2015) S127eS146 S143Objective: To acquaint transplant infusionists with SCIAR
causative factors and associated symptoms to guard for AE
during infusion.
Method: Study of published literature as available on
PubMed website in the last 7 years.
Result: 11 articles by authors from diverse nations were
reviewed. Only 1 publication is from USA. Reports
are for autologous cryopreserved HPC-A (including few
allogeneic or marrow products). 3 studies reported
SCIAR after DMSO wash. Data size is from 51-952 in-
fusions. AE ranges from 0.6 to 67%. Various symptoms
are reported.
Discussion: Minor AE are attributed to DMSO, AE from
washed cells to granulocyte or TNC content of graft.
Cordoba R et al have reported 67% SCIAR despite DMSO
wash. 7 years ago, Donmez A et al (Turkey) suggested re-
striction of infusion to <100 E+9 TNC; and Wang JW et al
(China) advised fractionated infusions (vs. single infusion)
in pediatric patients. Khera N et al (USA) have compared 2
groups over 2 years reporting 0.6% SCIAR on infusion of
<1.63 E+9 TNC/Kg/day, fractionating infusions on different
days.
Conclusion: Despite multiple variables, transplant
centers can lower incidence of SCIAR by restricting graft
dose.Table 2
Article Infusions AE % Finding/Symptoms
Feb 07
Donmez A, Turkey
194
Allo 25
25
0
Non cardiac > cardiac
Apr 07
Wang JW, China
Ped 70 x G-I
Jun 07
Mueller LP, Germany
51 2 Cardiac ^DMSO
Jul 07
Calmels B, France
490 (washed) 14 x
Nov 07
Foïs E, France
952 (washed) 19 x
Dec 07
Cordoba R, Spain
144 (washed) 67 Allergic > G-I >
Respiratory
2007
Milone G, Italy
HPC-A 157
HPC-M 22
31
5
Cardiac ^vol/kg & inf time
Non cardiac ^age & non-MNC
Jul 08
Bojanic I, Croatia
215 57 1 symptom 21%
>1 36%
Jul 10
Curcioli AC, Brazil
114
Allo 47
Haplo 5
58 DMSO but not DMSO vol
Oct 10
Martìn-Henao GA, Spain
423 25 G-I
Respiratory
Seizure 0.7%
Feb 12
Khera N, USA
(Comparative)
2006-07: 288
2008-09: 479
4
0.6
Infusions increased 4 fold165
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Introduction: Bendamustine is effective for front-line or
salvage therapy in patients (pts) with NHL. Benda-EAM
conditioning has been used in heavily pre-treated relapsed/
refractory lymphoma pts undergoing autologous stem cell
transplantation (AutoSCT) and is noted to be a safe and
effective regimen. We report our experience with using Be-
EAM conditioning regimen for AutoSCT with special note on
the toxicity proﬁle.
Methods: Data from 22 consecutive patients (pts), under-
going AutoSCT using the Be-EAM [Bendamustine200mg/m2
daily D-7,-6, Etoposide 200mg/m2 daily D-5 to -2, Ara-C
200mg/m2 Q12 D-5 to -2 and Melphalan 140mg/m2 on D-1],
treated at our institution between 2011 and 2013, were
collected. Demographics, indication for AutoSCT, time to
engraftment (TE), side effect proﬁle, tolerability and out-
comes were analyzed. WHO oral mucositis score was used
for grading mucositis.
Results: 22 pts (average age 60.36 yrs, range: 39-72 yrs)
were identiﬁed and analyzed as a retrospective cohort
with a follow-up duration of 26.1 months (Range 9-43
mos). 15 (68%) pts were male and 7 (32%) pts fe-
male. 72.7% were Caucasian. 8 (36.4%) pts had 2AE Cause Suggestion/Conclusion
Vol infused
DMSO
TNC
 100 E+9 TNC
Single vol infusion Fractionated infusion
Neurotoxicity unrelated to DMSO vol DMSO safe in neurologic disease
TNC Improve apheresis quality
TNC
Clumps
AE ^TNC
Granulocyte
Clumping
 6.065 E+9 granulocytes
Age
Non-MNC
 5.0 E+8 non-MNC
Female gender
Multiple myeloma
Granulocyte
AE ^graft composition & disease
DMSO Good documentation required
AE ^granulocyte x
x  1.63 E+9 TNC/Kg/Day
Multiple infusions
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refractory follicular lymphoma, diffuse large B cell lym-
phoma and lymphoplasmacytic lymphoma and upfront
consolidation for mantle cell lymphoma. 8 (36.4%) pts
underwent AutoSCT as consolidative therapy and 14
(63.6%) pts for relapsed/refractory disease. Therapies prior
to AutoSCT were 1-3 regimens. Time to engraftment was
11.71.79 days for neutrophils and 15.322.6 days for
platelets. Be-EAM-related toxicities included nausea,
emesis, diarrhea, neutropenic fever and mucositis. 13
(59%) pts had severe mucositis (Grade 3/4) with 5 pts
developing neutropenic enterocolitis including 1 patient
with pneumatosis intestinalis. Overall, 18 (81.8%) pts were
in CR and 2 (9%) pts had minimal disease at D100. 5
(22.7%) pts had relapsed disease. 4 (18.2%) pts died from
relapsed or progressive disease.
Conclusion: Bendamustine based conditioning is an effec-
tive regimen in patients with NHL undergoing autologous
stem cell transplantation as previously reported. It has the
potential of causing severe mucositis irrespective of age,
comorbidities, disease type or number of prior therapies.
This regimen although moderately tolerated should be used
cautiously especially in patients who have had prior thera-
pies that can affect the gastrointestinal tract.166
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Introduction: We have previously shown that as
compared with chemo-mobilization (CHM) cytokine
mobilization (CTM) is associated with a better chance ofTable 1
Primary Endpoint Analysis
Chemo-
mobilization
(N[19)
Cytokine
mobilization
(N[55)
p-value
Median total CD34 cells/kg
collected (in millions/kg):
Myeloma 14.9 8.37 0.01
Non-myeloma 4.47 5.03 0.71
Median number of apheresis
days (mean):
Myeloma 1 (1.75) 1 (1.76) 0.99
Non-myeloma 2 (1.67) 1 (1.59) 0.89
Target dose achieved: 0.05
Yes 16 (84.2%) 51 (92.7%)
No 3 (15.8%) 4 (7.3%)
Median day 1 CD34 collection
(in millions/kg):
0.01
Myeloma NA 6.86
Non-myeloma NA 3.67achieving a target autologous stem cell dose for patients
with multiple myeloma (MM). We now review our expe-
rience of autologous stem cell mobilization using a similar
strategy for all patients referred for an autologous trans-
plant (auto-SCT).
Methods: We analyzed consecutive patients who received
an auto-SCT for hematological malignancies at our center
from July 2010 to June 2013. CHM was achieved with
cyclophosphamide (4 g/m2), pegﬁlgrastim (12 mg) and
plerixafor (0.24 mg/kg once daily until target dose
collected or maximum of 4 days apheresis). CTM was
achieved with pegﬁlgrastim and plerixafor. We recorded
the total CD34+ cells/kg collection, number of apheresis
days, and if the prescribed dose of CD34+ cells/kg was
achieved. The prescribed cell dose in patients with MM is
6.0 x 106/kg, and 3.0 x 106/kg for all other hematological
malignancies. We compared the median total CD34+ cells/
kg dose collection (Wilcoxon test), the mean number of
apheresis days (Poission), and target stem cell dose
collection (non-inferiority test on two proportions). We
also compared day 1 stem cell collection in the CTM
group based on disease (myeloma vs. non-myeloma)
(Wilcoxon test). Finally, we analyzed the probability of
successful stem cell dose collection if the target collection
dose was higher than our own criteria.
Results: A total of 74 patients were included. Fifty-three
patients had a diagnosis of MM and twenty-one patients had
other hematological malignancies, non-Hodgkin (n¼15) and
Hodgkin lymphoma (n¼2). There was no statistically signif-
icant difference in age, gender, number of prior induction
treatment, prior treatment with lenalidomide and time from
diagnosis to transplant between the two groups. In the CHM
group, 7 (47%) were hospitalized from complications of
mobilization regimen, whereas no patients were hospital-
ized in the CTM group (p<0.001). There was no statistically
signiﬁcant difference in neutrophil or platelet engraftment
between CHM and CTM. Multivariate analysis did not reveal
predictive factors which lead to>1 apheresis attempts. Table
1 describes the primary outcomes.
Conclusion: Cytokine-mobilization with pegﬁlgrastim and
planned plerixafor is an effective strategy for stem cell mobi-
lization in patients being considered for autologous transplant.
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Background: Serum biomarkers in classical Hodgkin Lym-
phoma (cHL) reﬂect both tumor biology and burden in the
non-transplant setting.We sought to determine the prognostic
value of cHL serum biomarkers in predicting early relapse
following autologous stem cell transplantation (ASCT).
